Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Infertility is a global health issue as its affects both men and women. Female infertility is defined as the condition wherein a female cannot get pregnant even after one year of unprotected sexual activity. Infertility in females occur due to rising age, polycystic ovarian syndrome (PCOS), obesity, and multiple miscarriages. 

Global Female Infertility Treatment Drugs Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 169 million cases and 3.5 million deaths due to coronavirus disease (COVID-19) were reported till May 30, 2021 across the globe.

Impact of COVID-19 on Demand and Supply of Female Infertility Treatment Drugs

The emergence of the global pandemic has triggered fear that the global and extended pharmaceutical supply chain would crumble. In practice, it has proved remarkably resilient with drug shortages kept to a minimum. In addition, the pandemic has exposed some weaknesses in the supply chain that must be addressed as the world recovers and prepares for what the future holds.

The heavy reliance on China for raw materials, intermediates, and APIs as well as India for generic drug products remains a significant concern. Distribution is also affected by disruptions in the global supply chain, as are clinical trials. A high level of ambiguity is expected to remain until the spread of the SARS-CoV-2 virus is halted.

Furthermore, this heavy reliance of drugs leads to drug shortage in the U.S. For instance, the U.S. FDA reported an increase in the number of drug shortages from 2017 to 2018, a contrast to the declines observed since 2011. The drug shortages are lasting longer and can be even more than eight years in some cases. Over 60% of shortages in 2019 were attributed to supply disruptions due to manufacturing and/or quality issues due to covid-19 pandemic.

In addition to the reduction in manufacturing activity, the pharmaceutical supply chain is being impacted by distribution challenges created by reduced transportation capacity. Disruptions at ports, quarantined crews, and labor shortages due to lockdowns are all contributing factors.

The global female infertility treatment drugs market is estimated to be valued at US$ 2,649.8 Mn in 2021 and is expected to reach US$ 3,512.8 Mn by 2028, registering a CAGR of 4.1% during the forecast period (2021-2028)

Figure 1: Global Female Infertility Treatment Drugs Market Y-o-Y Growth Comparison (%), by Route of Administration, 2018-2028

Female Infertility Treatment Drugs  | Coherent Market Insights

The increasing rate of infertility is the major factor that is expected to drive the market growth over the forecast period.

Factor such as the increasing infertility rates globally is expected to augment the growth of global female infertility treatment drugs market over the forecast period. For instance, according to the report published in Galadari Printing and Publishing LLC, 2018, the prevalence of infertility increased with a significant decline in demographics ranging from 6.6 births per woman in the 1970s to 5.22 children in 1980-1985 and 1.73 from 2015-2020, registering an overall decrease of 160%.

Moreover, increasing number of research and development activities for improving the effectiveness of female infertility treatment drugs is expected to aid in the growth of the market over the forecast period. For instance, in October 2018, Myovant Sciences, a subsidiary of Sumitovant Biopharma, announced the presentation of data from a Phase 1 trial of MVT-602, a novel kisspeptin-1 receptor agonist in development as a potential treatment for female infertility in women as part of assisted reproduction, such as in vitro fertilization (IVF) at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress. Results of the study showed that administration of MVT-602 in healthy premenopausal women in the follicular phase produced a dose-related increase in luteinizing hormone concentrations and expected effects on follicle-stimulating hormone and estradiol).

The rising number of product approvals and launches support the research and development of new drugs for female infertility treatment which is expected to drive the growth of the global female infertility drugs market over the forecast period. For instance, in February 2016, Merck KGaA, a Germany-based science and technology company in healthcare, life science and performance materials, received approval from the European Medicines Agency (EMA) for the GONAL-f prefilled pen 2.0. GONAL-f (follitropin alfa), a recombinant human follicle-stimulating hormone (r-hFSH) approved for the treatment of infertility in both males and females. In November 2018, Merck & Co. Inc., announced that the company received approval for a new version of GONAL-f (follitropin alfa injection) prefilled pen from the U.S. Food and Drug Administration (U.S. FDA). Follitropin alfa helps stimulate healthy ovaries to produce eggs. It is known as GONAL-f RFF Redi-jectTM prefilled pen in the U.S.

In addition, increasing number of available reimbursement facilities by manufacturer and government propel the market growth of female infertility treatment drugs. For instance, Sanofi S.A. provides reimbursement for CLOMID under the Pharmaceutical Benefits Scheme (PBS) in Europe and Australia, in order to make the medicines available at affordable prices for patients. PBS provides timely, reliable, and affordable access to fertility medications to the people in Europe and Australia. The medicine is prescribed for the treatment of ovulatory failure in selected infertile women who wish to become pregnant.

request-sample

Female Infertility Treatment Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 2,649.8 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 4.1% 2028 Value Projection: US$ 3,512.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Segments covered:
  • By Therapy: Gonadotropins, Clomiphene, Letrozole, Metformin, Leuprolide Acetate, Bromocriptine, Estrogens, Ganirelix acetate, Cetrotide acetate, Progesterone
  • By Route Of Administration: Oral, Injectable
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

Ferring Pharmaceuticals, Merck & Co., Inc., Bayer AG, Abbott Laboratories, Par Pharmaceutical, Inc., Sumitovant, Livzon, Zydus Cadila, Oxolife, and Mankind Pharma

Growth Drivers:
  • Increasing infertility rate in females
  • Increasing Research and Development Activities by the Market Players
  • Increasing strategic collaborations among the market players
  • Increasing Product Launches and Approvals
  • Rising healthcare expenditure
Restraints & Challenges:
  • Risks associated with female infertility treatment drugs
  • Increasing Product Recalls

Global Female Infertility Treatment Drugs Market – Restraints

However, growth of the female infertility drugs market may be hampered, owing to the risks associated with female infertility treatment drugs and increasing number of product recalls. For instance, on March 2, 2021 Ferring Pharmaceuticals voluntarily initiated recall of their infertility treatment drug Menopur 75 IU.

Global Female Infertility Treatment Drugs Market – Regional Analysis

On the basis of region, the global female infertility treatment drugs market is segmented into North America, Latin America, Europe, and Asia Pacific.

North America is expected to show growth in the global female infertility drugs market over the forecast period, owing to rising number of product launch and increase in female infertility rates. For instance, according to the Centers for Disease Control and Prevention (CDC) report of 2018, around 6% of women aged 15 to 44 years in the U.S. were unable to conceive after one year of continuous intercourse.

Europe female infertility treatment drugs market is estimated to be valued at US$ 1,035.1 Mn in 2021 and is expected to increase to US$ 1,355.0 Mn by 2028, exhibiting a CAGR of 3.9% during the forecast period. Approval of novel products by regulatory authorities and availability of government or private policies for aiding infertility treatment in the region is expected to drive growth of the Europe female infertility treatment drugs market in the near future. For instance, National Health Service (NHS), a government owned organization provides free infertility treatment to women. Private players such as Manchester Fertility Services Ltd. and CARE Fertility are involved in providing financial assistance for infertility treatment in U.K.

The female infertility treatment drugs market in the Asia Pacific is expected to gain momentum during the forecast period, owing to an increasing prevalence of infertility rates in the Asian population. For instance, according to the Indian Society of Assisted Reproduction (ISAR) report of 2017, infertility affects around 10 to 14% of the Indian population, with higher rates in urban areas where one out of six couples are affected from it.

Figure 2: Global Female Infertility Treatment Drugs Market Y-o-Y Growth (%) Comparison, by Region, 2018 – 2028

Female Infertility Treatment Drugs  | Coherent Market Insights

Global Female Infertility Treatment Drugs Market – Competitive Landscape

Major players operating in the global female infertility treatment  drugs market include Ferring Pharmaceuticals, Merck & Co., Inc., Bayer AG, Abbott Laboratories, Par Pharmaceutical, Inc., Sumitovant, Livzon, Zydus Cadila, Oxolife, and Mankind Pharma.

Female infertility refers to a condition where a woman is unable to conceive after at least one year of having unprotected sex. Various factors such as age, hormone imbalance, physical health, and lifestyle can lead to female infertility. Ovulation testing, Hysterosalpingography, and ovarian reserve testing are few of the tests used to diagnose female infertility. Ovarian reserve testing is highly recommended for women over the age of 35 years. Ovulation testing involves two tests viz. Luteinizing Hormone (LH) test and Follicle-Stimulating Hormone (FSH) test to check for ovulation which can aid in finding out the cause of infertility.

Female infertility can be treated using surgical methods such as Laparoscopic or hysteroscopic surgery and Tubal surgeries. These surgeries are performed to remove or correct abnormalities to help improve chances of getting pregnant. The surgeries can be performed to correct abnormal uterine shape, removing endometrial polyps and some types of fibroids that misshape the uterine cavity, or removing pelvic or uterine adhesions. In some cases, the fallopian tubes may be blocked or filled with fluid (hydrosalpinx). Tubal surgeries are performed to remove adhesions, dilate a tube or create a new tubal opening. Tubal surgeries are performed to remove adhesions, dilate a tube or create a new tubal opening. The global fertility rate is dropping at an alarming rate which is expected to drive the market growth of female infertility treatment drugs market over the forecast period. According to the Institute for Health Metrics and Evaluation, University of Washington, in 1950 the global fertility rate was 4.7 which halved to 2.4 in 2017 and is expected to drop as low as 1.7 in the near future.

Market Dynamics

Market players are focusing on various growth strategies such as agreements, partnerships, and collaborations to accelerate the development of drugs for infertility treatment, which is expected to boost growth of the global female infertility treatment drugs market over the forecast period. For instance, in January 2020, Bayer AG announced the expansion of their partnership with Evotec SE, a biotechnology company focusing on women health, with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), which is one of the causes of infertility in females.

Moreover, in January 2019, Ferring Pharmaceuticals, a biopharmaceutical company entered into an exclusive agreement with Sun Pharmaceutical Industries Ltd., an India-based multinational pharmaceutical company to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate injection which is used for treatment of female infertility.

Key features of the study:

  • This report provides an in-depth analysis of global female infertility treatment drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global female infertility treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Ferring Pharmaceuticals, Merck & Co., Inc., Bayer AG, Abbott Laboratories, Par Pharmaceutical, Inc., Sumitovant, Livzon, Zydus Cadila, Oxolife, and Mankind Pharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global female infertility treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the female infertility treatment drugs market

Detailed Segmentation:

  • Global Female Infertility Treatment Drugs Market, By Therapy:
    • Gonadotropins
    • Clomiphene
    • Letrozole
    • Metformin
    • Leuprolide Acetate
    • Bromocriptine
    • Estrogens
    • Ganirelix Acetate
    • Cetrotide Acetate
    • Progesterone
  • Global Female Infertility Treatment Drugs Market, By Route of Administration:
    • Oral
    • Injectable
  • Global Female Infertility Treatment Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Female Infertility Treatment Drugs Market, By Region:
    • North America
      • By Therapy:
        • Gonadotropins
        • Clomiphene
        • Letrozole
        • Metformin
        • Leuprolide Acetate
        • Bromocriptine
        • Estrogens
        • Ganirelix Acetate
        • Cetrotide Acetate
        • Progesterone
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Therapy:
        • Gonadotropins
        • Clomiphene
        • Letrozole
        • Metformin
        • Leuprolide Acetate
        • Bromocriptine
        • Estrogens
        • Ganirelix Acetate
        • Cetrotide Acetate
        • Progesterone
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Therapy:
        • Gonadotropins
        • Clomiphene
        • Letrozole
        • Metformin
        • Leuprolide Acetate
        • Bromocriptine
        • Estrogens
        • Ganirelix Acetate
        • Cetrotide Acetate
        • Progesterone
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Therapy:
        • Gonadotropins
        • Clomiphene
        • Letrozole
        • Metformin
        • Leuprolide Acetate
        • Bromocriptine
        • Estrogens
        • Ganirelix Acetate
        • Cetrotide Acetate
        • Progesterone
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Therapy:
        • Gonadotropins
        • Clomiphene
        • Letrozole
        • Metformin
        • Leuprolide Acetate
        • Bromocriptine
        • Estrogens
        • Ganirelix Acetate
        • Cetrotide Acetate
        • Progesterone
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Therapy:
        • Gonadotropins
        • Clomiphene
        • Letrozole
        • Metformin
        • Leuprolide Acetate
        • Bromocriptine
        • Estrogens
        • Ganirelix Acetate
        • Cetrotide Acetate
        • Progesterone
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Region/Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Ferring Pharmaceuticals*
      • Company Highlights
      • Therapys Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Merck & Co., Inc.
    • Bayer AG
    • Abbott Laboratories
    • Par Pharmaceutical, Inc.
    • Sumitovant
    • Livzon
    • Zydus Cadila
    • Oxolife
    • Mankind Pharma

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Therapy
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pipeline Analysis
    • Recent Therapy Approval/Launch
    • Key Developments
    • Collaborations & Partnerships; Mergers & Acquisition
    • Competitive landscape
    • Brand Attribute Mapping
    • PEST Analysis
    • Epidemiology
    • Fertility Rate
    • Awareness & Challenges
  4. Global Female Infertility Treatment Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact of COVID-19 on Supply Chain of Female Fertility Drugs
    • Impact of Covid-19 on Overall Healthcare Market
  5. Global Female Infertility Treatment Drugs Market, By Therapy, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Gonadotropins
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Clomiphene
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Letrozole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Metformin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Leuprolide Acetate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Bromocriptine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Estrogens
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Ganirelix Acetate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Cetrotide Acetate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Progesterone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Female Infertility Treatment Drugs Market, By Route of Administration, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Global Female Infertility Treatment Drugs Market, By Distribution Channel, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  8. Global Female Infertility Treatment Drugs Market, By Region, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Million, No. of Units in Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Million, No. of Units in Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Million, No. of Units in Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Million, No. of Units in Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Million, No. of Units in Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 – 2028, (US$ Million, No. of Units in Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2028, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Ferring Pharmaceuticals
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Merck & Co, Inc.
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bayer AG
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Abbott Laboratories
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Par Pharmaceutical Inc.
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sumitovant
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Livzon
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Zydus Cadila
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mankind Pharma
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Oxolife
        • Company Highlights
        • Therapys Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
    • Analyst Views
  10. Section
    • Research Methodology
    • About us
    • Contact

*Browse 33 market data tables and 25 figures on "Female Infertility Treatment Drugs Market” - Global Forecast to 2028.

FAQgrowicon

Frequently Asked Questions

The global female infertility treatment drugs market is expected to exhibit a CAGR of 4.1% during the forecast period (2021-2028).
The market is estimated to be valued at US$ US$ 2,649.8 Mn in 2021.
Ferring Pharmaceuticals, Merck & Co., Inc., Bayer AG, Abbott Laboratories, Par Pharmaceutical, Inc., Sumitovant, Livzon, Zydus Cadila, Oxolife, and Mankind Pharma are some of the prominent players operating in the market.
The market is expected to be valued at US$ 3,512.8 Mn in 2028.
Europe is the prominent region in the market.
Increasing number product launch, rising cases of female infertility, increasing research and development activities by the market players, and increasing strategic collaborations among the market players are some of the driving factors, which are expected to drive growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner